nach oben

Erschienen in:

28.07.2019 | Glioblastom | Zertifizierte Fortbildung

Neuroonkologie

Aktuelle Ansätze der Immuntherapie maligner Gliome

verfasst von: Dr. med. Hanna Maria Meister, Prof. Dr. med. Elke Hattingen, Prof. Dr. med. Uwe Schlegel

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Maligne Gliome weisen trotz multimodaler Therapie eine schlechte Prognose auf. Innovative immuntherapeutische Verfahren haben die Behandlungsmöglichkeiten zahlreicher Tumore entscheidend verbessert und bieten auch für die Neuroonkologie neue Therapieansätze, die in diesem Artikel dargestellt werden.

Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 20102–2014. Neuro Oncol 2017; 19(suppl_5):v1–88CrossRef

Weller M, van den Bent M, Hopkins K, Tonn JC, Stupp R, Falini A et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014; 15(9):e395–403CrossRef

Oberoi RK, Parrish KE, Sio TT, Mittapalli RK, Elmquist WF, Sarkaria JN. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro Oncol 2016; 18(1):27–36CrossRef

Louveau A, Plog BA, Antila S, Alitalo K, Nedergaard M, Kipnis J. Understanding the functions and relationships of the glymphatic system and meningeal lymphatics. J Clin Invest 2017; 127(9): 3210–9CrossRef

Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015; 523(7560): 337–41CrossRef

Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid ?. Sci Transl Med 2012; 4(147): 147ra111–147ra111CrossRef

Champiat S, Ferté C, Lebel-Binay S, Eggermont A, Soria JC. Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology 2014; 3(1): e27817CrossRef

Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H et al. The Immune Landscape of Cancer. Immunity 2018; 48(4): 812–830.e14CrossRef

Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: Implications for immune checkpoint immunotherapy. Neuro Oncol 2017; 19(8): 1047–57CrossRef

10.

Van Den Bent MJ, Gao Y, Kerkhof M, Kros JM, Gorlia T, Van Zwieten K et al. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro Oncol 2015; 17(7): 935–41CrossRef

11.

Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (80- ) 2014; 343(6167): 189–93CrossRef

12.

Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A, Malzkorn B et al. Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: Prognostic role and comparison between primary and recurrent tumors. Clin Cancer Res 2017; 23(22): 6846–55CrossRef

13.

Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R et al. A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape. J Immunol 2002; 168(9): 4772–80CrossRef

14.

Wischhusen J, Friese MA, Mittelbronn M, Meyermann R, Weller M. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: Implications for immune escape in vivo. J Neuropathol Exp Neurol 2005; 64(6): 523–8CrossRef

15.

Mangani D, Weller M, Roth P. The network of immunosuppressive pathways in glioblastoma. Biochem Pharmacol 2017; 130: 1–9CrossRef

16.

Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 2018; 15(7): 422–42CrossRef

17.

Weller M, Kaulich K, Hentschel B, Felsberg J, Gramatzki D, Pietsch T et al. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer 2014; 134(10): 2437–47CrossRef

18.

Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28(31): 4722–9CrossRef

19.

Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011; 13(3): 324–33CrossRef

20.

Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: The ACT III study. Neuro Oncol 2015; 17(6): 854–61CrossRef

21.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 2017; 18(10): 1373–85CrossRef

22.

Reardon D, Schuster J, Tran D, Fink K, Nabors L, Li G et al. IT-30ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA. Neuro Oncol 2014; 16(suppl_5): v116–v116

23.

Gatson NTN, Weathers S-PS, de Groot JF. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma (retracted). CNS Oncol 2016; 5(1): 11–26CrossRef

24.

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med 2009; 360(8): 765–73CrossRef

25.

Schumacher T, Bunse L, Pusch S, Sahm F, Wiestler B, Quandt J et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014; 512(7514): 324–7CrossRef

26.

Platten M, Schilling D, Bunse L, Wick A, Bunse T, Riehl D et al. ATIM-33. NOA-16: a first-in-man multicenter phase I clinical trial of the german neurooncology working group evaluating a mutation-specific peptide vaccine targeting idh1r132h in patients with newly diagnosed malignant astrocytomas Neuro Oncol 2018; 20(suppl_6): vi8–vi9CrossRef

27.

Rampling R, Peoples S, Mulholland PJ, James A, Al-Salihi O, Twelves CJ et al. A cancer research UK first time in human phase i trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin Cancer Res 2016; 22(19): 4776–85CrossRef

28.

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovič S, Gouttefangeas C et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 2019; 565: 240–5CrossRef

29.

Weiss T, Weller M, Roth P. Immunotherapy for glioblastoma: Concepts and challenges. Curr Opin Neurol 2015; 28(6): 639–46CrossRef

30.

Filley AC, Dey M. Dendritic cell based vaccintion strategy: an evolving paradigm. J Neurooncol 2017; 133: 223–135CrossRef

31.

Wen P, Reardon D, Phuphanich S, Aiken R, Landolfi J, Curry W et al. AT-60 * A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 2 TRIAL OF DENDRITIC CELL (DC) VACCINE ICT-107 FOLLOWING STANDARD TREATMENT IN NEWLY DIAGNOSED PATIENTS WITH GBM. Neuro Oncol 2014; 16(suppl 5): v22–v22CrossRef

32.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med 2018; 16(1): 142CrossRef

33.

Wick W, van den Bent M. First results on DCVax phase III trial: raising more questions than providing answers. Neuro Oncol 2018; 20(10): 1283–4CrossRef

34.

Rapp M, Grauer OM, Kamp M, Sevens N, Zotz N, Sabel M et al. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): Study protocol for a randomized controlled trial. Trials 2018; 19(1): 293CrossRef

35.

Constantino J, Gomes C, Falcão A, Neves BM, Cruz MT. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res 2017; 65(4): 798–810CrossRef

36.

Leone P, Shin EC, Perosa F, Vacca A, Dammacco F, Racanelli V. MHC class i antigen processing and presenting machinery: Organization, function, and defects in tumor cells. J Natl Cancer Inst 2013; 105(16): 1172–87CrossRef

37.

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12(4): 252–64CrossRef

38.

Kamath SD, Kumthekar PU. Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease. Front Oncol 2018; 8: 414CrossRef

39.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med 2018; 379(8): 722–30CrossRef

40.

Tan AC, Heimberger AB, Menzies AM, Pavlakis N, Khasraw M. Immune Checkpoint Inhibitors for Brain Metastases. Curr Oncol Rep 2017; 19(6): 38CrossRef

41.

Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH et al. Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res 2016; 4(2): 124–35CrossRef

42.

Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res 2017; 23(1): 124–36CrossRef

43.

Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM et al. IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clin Cancer Res 2018; 24(11): 2559–73CrossRef

44.

Wainwright DA, Chang AL, Dey M, Balyasnikova I V, Kim CK, Tobias A et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 2014; 20(20): 5290–301CrossRef

45.

Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys 2013; 86(2): 343–9CrossRef

46.

Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol 2016; 18(2): 195–205CrossRef

47.

Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol 2015; 17(8): 1064–75CrossRef

48.

Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, Sepulveda J et al. OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143. Neuro Oncol 2017; 19(suppl_3): iii21CrossRef

49.

Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: Results from exploratory phase i cohorts of CheckMate 143. Neuro Oncol 2018; 20(5): 674–86CrossRef

50.

Reardon DA, Sampson JH, Sahebjam S, Lim M, Baehring JM, Vlahovic G et al. Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143. J Clin Oncol 2016; 34(15_suppl): 2014CrossRef

51.

Lim M, Omuro A, Vlahovic G, Reardon DA, Sahebjam S, Cloughesy T et al. 325ONivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM). Ann Oncol 2017; 28(suppl_5)

52.

Sampson JH, Omuro AMP, Preusser M, Lim M, Butowski NA, Cloughesy TF et al. A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. J Clin Oncol 2016; 34(15_suppl): TPS2079CrossRef

53.

Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med 2019; 25(3): 477–86CrossRef

54.

Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med 2019; 25(3): 470–6CrossRef

55.

Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med 2019; 25(3): 462–9CrossRef

56.

Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci 1989; 86(24): 10024–8CrossRef

57.

Rodriguez A Brown C Badie B.Chimeric antigen receptor T-cell therapy for glioblastoma. Transl Res 2017;18793-10

58.

Migliorini D, Dietrich PY, Stupp R, Linette GP, Posey AD, June CH. CAR T-cell therapies in glioblastoma: A first look. Clin Cancer Res 2018; 24(3): 535–40CrossRef

59.

Leung W-H, Gay J, Martin U, Garrett TE, Horton HM, Certo MT et al. Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization. JCI Insight 2019; 4(11)

60.

Valton J, Guyot V, Boldajipour B, Sommer C, Pertel T, Juillerat A, et al. A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies. Sci Rep 2018; 8(1): 8972CrossRef

61.

Cho JH, Collins JJ, Wong WW. Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses. Cell 2018; 173(6): 1426–1438.e11CrossRef

62.

O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017; 9(399): piieaaa0984CrossRef

63.

Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC et al. Bioactivity and safety of IL13R?2-redirected chimeric antigen receptor CD8+T cells in patients with recurrent glioblastoma. Clin Cancer Res 2015; 21(18): 4062–72CrossRef

64.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Wakefield A, Ghazi A et al. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma. JAMA Oncol 2018; 3(8): 1094–101CrossRef

65.

Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med 2016; 375(26): 2561–9CrossRef

66.

Roth P, Valavanis A, Weller M. Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. Neuro Oncol 2017; 19(3): 454–6PubMed

67.

Okada H, Weller M, Huang R, Finocchiaro G, Pollack IF, Brandes AA et al. Immunotherapy Response Assessment in Neuro-Oncology (iRANO): A Report of the RANO Working Group. Lancet Oncol 2015; 16(15): e534–42CrossRef

Titel: Neuroonkologie
Aktuelle Ansätze der Immuntherapie maligner Gliome
verfasst von: Dr. med. Hanna Maria Meister
Prof. Dr. med. Elke Hattingen
Prof. Dr. med. Uwe Schlegel
Publikationsdatum: 28.07.2019
Verlag: Springer Medizin
Schlagwörter: Glioblastom
Gliome
Glioblastom
Gliome
Gliome
Glioblastom
Checkpoint-Inhibitoren
Checkpoint-Inhibitoren
CAR-T-Zellen
Erschienen in: DNP – Die Neurologie & Psychiatrie / Ausgabe 4/2019
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI: https://doi.org/10.1007/s15202-019-2114-y

Passend zum Thema

Neue ESMO-Clinical Practice Guidelines 2023 zum fortgeschrittenen mNSCLC

Mit dem Update der Clinical Practice Guidelines 2023 zum metastasierenden nicht-kleinzelligen Lungenkarzinom (mNSCLC) trägt die ESMO der in den letzten Jahren immer weiter gewachsenen Anzahl an Therapieoptionen Rechnung.

NOVUM Onkologie – Fortbildungsreihe zum NSCLC

Mit NOVUM Onkologie veranstaltet MSD regelmäßig Online-Fortbildungen zum Thema Lungenkarzinom. Bei dem mittlerweile etablierten Format erhalten Teilnehmende die Möglichkeit sich bei Expertendiskussionen zu praxisrelevanten Themen der pneumologischen Onkologie weiterzubilden.

Fokus Immunonkologie – NSCLC

Content Hub

Die Einführung von Immun-Checkpoint-Inhibitoren markierte einen entscheidenden Fortschritt in der Behandlung von bestimmten Patienten mit nicht-kleinzelligem Lungenkarzinom (non-small cell lung cancer, NSCLC) und eröffnete seither neue Perspektiven und Chancen für Behandler und geeignete Patienten. Hier finden Sie fortlaufend aktuelle Informationen und relevante Beiträge zur Immunonkologie in dieser Indikation.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2019

Master im Multiple-Sklerose-Management

Atomoxetin generisch

Neue Ansätze bei ALS und Migräne

Zentrale Muskelrelaxation

Reduktion von Migräneattacken durch Blockade von CGRP

Gentherapie gegen SMA

Passend zum Thema

Neue ESMO-Clinical Practice Guidelines 2023 zum fortgeschrittenen mNSCLC

NOVUM Onkologie – Fortbildungsreihe zum NSCLC

Fokus Immunonkologie – NSCLC